论文部分内容阅读
嵌合抗原受体T(CAR-T)细胞是近年来迅速发展的肿瘤过继性免疫治疗新手段。其主要特点是通过基因工程改造获得识别肿瘤抗原特异性受体的T细胞并赋予其靶向性、杀伤性及持久性的治疗方法。1989年首次提出CAR-T,现已经发展到第四代,且多研究中心对CD19-CAR-T细胞治疗技术进行了I期临床研究显示出活性。CAR-T疗法是目前有望治愈复发难治性血液肿瘤的新方法。
Chimeric antigen receptor T (CAR-T) cells are a new means of adoptive immunotherapy of tumor in recent years. Its main feature is the genetic modification of T cells that recognize tumor antigen-specific receptors and give them targeted, lethal and long-lasting treatment. CAR-T, first proposed in 1989, has now been extended to the fourth generation and many research centers have demonstrated Phase I clinical studies of CD19-CAR-T cell therapy. CAR-T therapy is currently a new method of curing refractory hematologic malignancies.